Article (Scientific journals)
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Bonnefoi, H.; Jacot, W.; Saghatchian, M. et al.
2014In Annals of Oncology
Peer Reviewed verified by ORBi
 

Files


Full Text
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab ....pdf
Author postprint (5.83 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Breast cancer; HER2; lapatinib; neoadjuvant chemotherapy; pathological response; trastuzumab
Abstract :
[en] BACKGROUND: Neoadjuvant trials conducted using a double HER2-blockade with lapatinib and trastuzumab, combined with different paclitaxel-containing chemotherapy regimens, have shown high pathological complete response (pCR) rates, but at the cost of important toxicity. We hypothesised that this toxicity might be due to a specific interaction between paclitaxel and lapatinib. This trial assesses the toxicity and activity of the combination of docetaxel with lapatinib and trastuzumab. PATIENTS AND METHODS: Patients with stage IIA to IIIC HER2-positive breast cancer received six cycles of chemotherapy (three cycles of docetaxel followed by three cycles of fluorouracil, epirubicin, cyclophosphamide). They were randomised 1:1:1 to receive during the first three cycles either lapatinib (1000 mg orally daily), trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly), or trastuzumab+lapatinib at the same dose. The primary endpoint was pCR rate defined as ypT0/is. Secondary endpoints included safety and toxicity. pCR rate defined as ypT0/is ypN0 was assessed as an exploratory analysis. In June 2012, arm A was closed for futility based on the results from other studies. RESULTS: From October 2010 to January 2013, 128 patients were included in 14 centres. The percentage of the 122 evaluable patients with pCR in the breast, and pCR in the breast and nodes, was numerically highest in the lapatinib+trastuzumab group (60% and 56%, respectively), intermediate in the trastuzumab group (52% and 52%), and lowest in the lapatinib group (46% and 36%). Frequency (%) of the most common grade 3-4 toxicities in the lapatinib /trastuzumab/lapatinib+trastuzumab arms were: febrile neutropenia 23/15/10, diarrhea 9/2/18, infection (other) 9/4/8, and hepatic toxicity 0/2/8. CONCLUSIONS: This study demonstrates a numerically modest pCR rate increase with double anti-HER2 blockade plus chemotherapy, but suggests that the use of docetaxel rather than paclitaxel may not reduce toxicity. This study is registered with ClinicalTrials.gov, number NCT00450892.
Disciplines :
Oncology
Author, co-author :
Bonnefoi, H.
Jacot, W.
Saghatchian, M.
Moldovan, C.
Venat-Bouvet, L.
Zaman, K.
Matos, E.
Petit, T.
Bodmer, A.
Quenel-Tueux, N.
Chakiba, C.
Vuylsteke, P.
Jerusalem, Guy  ;  Université de Liège - ULiège > Département des sciences cliniques > Oncologie
Brain, E.
Tredan, O.
Messina, C. G. M.
Slaets, L.
Cameron, D.
More authors (8 more) Less
Language :
English
Title :
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Publication date :
2014
Journal title :
Annals of Oncology
ISSN :
0923-7534
eISSN :
1569-8041
Publisher :
Oxford University Press, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
(c) The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Available on ORBi :
since 15 January 2015

Statistics


Number of views
35 (0 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
62
Scopus citations®
without self-citations
59
OpenCitations
 
52

Bibliography


Similar publications



Contact ORBi